HIV

The study authors note that addressing environmental factors, such as IPV and food insecurity, can provide further benefits in neurodevelopment regardless of maternal HIV status.

Further research of these mechanisms could be significant in developing future strategies to disrupt the viral persistence in individuals living with HIV.

According to the authors, current HIV care methods demonstrate that the mean age at death for Black MSM was 68.8 years, whereas the mean age for White MSM was 75.6 years.

Combination prevention strategies reduced the number of new HIV infections among gay and bisexual men who have sex with men; however, improvement of current methods is needed to meet the 2025 and 2030 reduction goals.

The finding indicates that a potential vaccine can trigger a permanent response in individuals living with HIV-1.

Study results indicate that outcomes were worse among those who inject illicit drugs and Black patients living with HIV.

Not only is the test significant for identifying HIV and TB, but it can be safer for patients living with HIV due to their suppressed immune systems.

Although the initiation was high, only 33% of adolescent girls and young women continued PrEP use through the 6-month follow-up.

Biktarvy was found both effective and safe for long-term use in HIV, as well as for patients with mental health conditions.

Investigators suggest that the Bacille Calmette–Guérin vaccine, which prevented tuberculosis in nonhuman primates infected with SIV, can also protect against HIV.

Health promotional strategies should account for social contexts and cultural perspectives to increase the number of individuals who choose to test for HIV.

Study shows that interventions may help to personalize care that meets the individual needs of patients with HIV and to improve mental health outcomes.

The hydrogel injection has had a lasting drug concentration of 42 days with almost no adverse effects.

Monoclonal antibody treatment resulted in suppression of HIV for more than 3 months, with some continuing to suppress the virus for more than 18 months after treatment stopped.

Two separate study findings reported that a subset of dormant CD4+ cells could spontaneously produce HIV RNA and proteins, impacting a patient’s HIV-specific immune responses.

Moderna has advanced 6 programs into late-stage development, including for respiratory conditions, latent and other viruses, oncology, and rare diseases.

Strategies include improving compliance, convenience, symptom management, and reducing stigma around pre-exposure prophylaxis for HIV.

Telemedicine approaches for HIV can help reduce stigma that is often a challenge in face-to-face clinical settings and eliminate common logistical barriers, such as transportation.

Combining T and B cell vaccines could induce a strong enough immune response and protect against HIV-1 infection, although the science is not fully developed.

Although antiretroviral therapies are the standard of care treatment for those with HIV, the drugs cannot target latent infections; however, venetoclax, a blood cancer treatment, shows promise.

The fixed-dose abacavir/dolutegravir/lamivudine combination is indicated for the once-daily treatment of children weighing at least 6 kg to <25 kg with HIV-1 infection.

A combination of statin therapy and antiretroviral therapy may decrease the naturally higher risk of cardiovascular disease in patients with HIV.

Previous studies have shown promising results with liver or kidney transplants in patients with HIV, but there was a lack of literature regarding heart transplants specifically.

Topics discussed include care workflow, app functionalities, problems and disadvantages, and benefits for HIV experts.

The burden of aging-related comorbidities was higher across every age category in women compared to men, and increased with age.

The findings suggest that CHD1L’s could provide treatment opportunities for individuals infected with HIV-1.

Rilpivirine is part of the first ever long-acting injectable HIV-1 treatment option for children aged 12 years and older.

Patients with HIV can donate a kidney to others with HIV who have a low risk of developing end-stage renal disease or other kidney problems for 2 to 4 years following donation.

The low risk of cardiovascular events was observed in all relevant subgroups, including in both males and females with HIV.

Patients with a low but detectable viral load posed virtually no risk of passing HIV on to their sexual partner if they were taking WHO-recommended antiretroviral therapy.